临床实践中多参数磁共振成像技术用于疑似前列腺癌患者评估的实施效果
结果显示,MRI组活检比例降低18.7%(45.6% vs 56.1%,P < 0.001),但总体前列腺癌检出率(56.8% vs 40.7%,P < 0.001)和临床显著前列腺癌检出率(47.3% vs 31.0%,P < 0.001)均显著高于仅PSA组。结论表明,在临床实践中加入MRI可提高临床显著前列腺癌的检出率,同时降低前列腺活检率。
要点
- MRI组活检比例较仅PSA组降低18.7%(45.6% vs 56.1%,P < 0.001)。
- MRI组总体前列腺癌检出率更高(56.8% vs 40.7%,P < 0.001)。
- MRI组临床显著前列腺癌检出率更高(47.3% vs 31.0%,P < 0.001)。
核心结论
- 在临床疑似前列腺癌的男性中,加入MRI可提高临床显著前列腺癌的检出率,同时降低前列腺活检率。
主要发现
- MRI组465例(45.6%)接受活检,仅PSA组442例(56.1%)接受活检,MRI组活检比例降低18.7%(P < 0.001)。
- MRI组总体前列腺癌检出率为56.8%,仅PSA组为40.7%(P < 0.001)。
- MRI组临床显著前列腺癌检出率为47.3%,仅PSA组为31.0%(P < 0.001)。
- 多因素logistic回归调整临床相关变量后,MRI组总体前列腺癌检出(OR 1.74,95%CI 1.29-2.35;P < 0.001)和临床显著前列腺癌检出(OR 2.04,95%CI 1.48-2.80;P < 0.001)的OR均高于仅PSA组。
临床怎么用
- 对于临床疑似前列腺癌的男性,可考虑在活检前使用MRI进行风险分层,以提高临床显著前列腺癌的检出率并减少不必要的活检。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the impact of implementing magnetic resonance imaging (MRI) and ultrasonography fusion technology on biopsy and prostate cancer (PCa) detection rates in men presenting with clinical suspicion for PCa in the clinical practice setting. PATIENTS AND METHODS: We performed a review of 1 808 consecutive men referred for elevated prostate-specific antigen (PSA) level between 2011 and 2014. The study population was divided into two groups based on whether MRI was used as a risk stratification tool. Univariable and multivariable analyses of biopsy rates and overall and clinically significant PCa detection rates between groups were performed. RESULTS: The MRI and PSA-only groups consisted of 1 020 and 788 patients, respectively. A total of 465 patients (45.6%) in the MRI group and 442 (56.1%) in the PSA-only group underwent biopsy, corresponding to an 18.7% decrease in the proportion of patients receiving biopsy in the MRI group (P < 0.001). Overall PCa (56.8% vs 40.7%; P < 0.001) and clinically significant PCa detection (47.3% vs 31.0%; P < 0.001) was significantly higher in the MRI vs the PSA-only group. In logistic regression analyses, the odds of overall PCa detection (odds ratio [OR] 1.74, 95% confidence interval [CI] 1.29-2.35; P < 0.001) and clinically significant PCa detection (OR 2.04, 95% CI 1.48-2.80; P < 0.001) were higher in the MRI than in the PSA-only group after adjusting for clinically relevant PCa variables. CONCLUSION: Among men presenting with clinical suspicion for PCa, addition of MRI increases detection of clinically significant cancers while reducing prostate biopsy rates when implemented in a clinical practice setting.
引用
- Shah PH, Patel VR, Moreira DM, et al. Implementation of multiparametric magnetic resonance imaging technology for evaluation of patients with suspicion for prostate cancer in the clinical practice setting. BJU Int. 2018. PMID: 30113138. doi:10.1111/bju.14515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。